1 - 25 of 36 results for author:"Schuppan D." in Literature citations
Results Customize
› Repeat search in UniProtKB (7)
| Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Schattenberg J.M., Nagel M., Kim Y.O., Kohl T., Worns M.A., Zimmermann T., Schad A., Longerich T., Schuppan D., He Y.W. et al. Am. J. Physiol. Gastrointest. Liver Physiol. 303:G498-506(2012) · Mapped (4) |
| Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Seven G., Karatayli S.C., Kose S.K., Yakut M., Kabacam G., Toruner M., Heper A.O., Voelker M., Erden E., Bozdayi A.M. et al. Turk J Gastroenterol 22:305-314(2011) · Mapped (2) |
| IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Urban T.J., Thompson A.J., Bradrick S.S., Fellay J., Schuppan D., Cronin K.D., Hong L., McKenzie A., Patel K., Shianna K.V. et al. Hepatology 52:1888-1896(2010) · Mapped (1) |
| Human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis. Freitag T.L., Cham C., Sung H.H., Beilhack G.F., Durinovic-Bello I., Patel S.D., Bronson R.T., Schuppan D., Sonderstrup G. Gastroenterology 139:281-291(2010) · Mapped (306) |
| Role of the receptor for advanced glycation end products in hepatic fibrosis. Lohwasser C., Neureiter D., Popov Y., Bauer M., Schuppan D. World J. Gastroenterol. 15:5789-5798(2009) · Mapped (6) |
| The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. Malik R., Chang M., Bhaskar K., Nasser I., Curry M., Schuppan D., Byrnes V., Afdhal N. J. Gastroenterol. Hepatol. 24:564-568(2009) · Mapped (4) |
| Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense decrements of oxygen but not hypoxia per se. Millonig G., Hegedusch S., Becker L., Seitz H.K., Schuppan D., Mueller S. Free Radic. Biol. Med. 46:182-191(2009) · Mapped (9) |
| Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. Omenetti A., Porrello A., Jung Y., Yang L., Popov Y., Choi S.S., Witek R.P., Alpini G., Venter J., Vandongen H.M. et al. J. Clin. Invest. 118:3331-3342(2008) · Mapped (9) |
| Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Patsenker E., Popov Y., Stickel F., Jonczyk A., Goodman S.L., Schuppan D. Gastroenterology 135:660-670(2008) · Mapped (19) |
| No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Stickel F., Osterreicher C.H., Halangk J., Berg T., Homann N., Hellerbrand C., Patsenker E., Schneider V., Kolb A., Friess H. et al. Alcohol. Clin. Exp. Res. 32:959-965(2008) · Mapped (2) |
| Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. Popov Y., Patsenker E., Stickel F., Zaks J., Bhaskar K.R., Niedobitek G., Kolb A., Friess H., Schuppan D. J. Hepatol. 48:453-464(2008) · Mapped (12) |
| Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Kunzli B.M., Nuhn P., Enjyoji K., Banz Y., Smith R.N., Csizmadia E., Schuppan D., Berberat P.O., Friess H., Robson S.C. Gastroenterology 134:292-305(2008) · Mapped (8) |
| Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. Patsenker E., Popov Y., Wiesner M., Goodman S.L., Schuppan D. J. Hepatol. 46:878-887(2007) · Mapped (5) |
| Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. Huether A., Hopfner M., Sutter A.P., Baradari V., Schuppan D., Scherubl H. World J. Gastroenterol. 12:5160-5167(2006) · Mapped (19) |
| The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. Lohwasser C., Neureiter D., Weigle B., Kirchner T., Schuppan D. J. Invest. Dermatol. 126:291-299(2006) · Mapped (36) |
| Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Homann N., Stickel F., Konig I.R., Jacobs A., Junghanns K., Benesova M., Schuppan D., Himsel S., Zuber-Jerger I., Hellerbrand C. et al. Int. J. Cancer 118:1998-2002(2006) · Mapped (2) |
| Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Stickel F., Osterreicher C.H., Datz C., Ferenci P., Wolfel M., Norgauer W., Kraus M.R., Wrba F., Hellerbrand C., Schuppan D. Arch. Intern. Med. 165:1835-1840(2005) · Mapped (16) |
| The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes. Ruehl M., Erben U., Schuppan D., Wagner C., Zeller A., Freise C., Al-Hasani H., Loesekann M., Notter M., Wittig B.M. et al. J. Biol. Chem. 280:38537-38543(2005) · Mapped (5) |
| VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Li Z.D., Bork J.P., Krueger B., Patsenker E., Schulze-Krebs A., Hahn E.G., Schuppan D. Biochem. Biophys. Res. Commun. 334:1049-1060(2005) · Mapped (20) |
| Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. Reis R.C., Schuppan D., Barreto A.C., Bauer M., Bork J.P., Hassler G., Coelho-Sampaio T. Biochem. Biophys. Res. Commun. 333:976-983(2005) · Mapped (2) |
| TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Osterreicher C.H., Datz C., Stickel F., Hellerbrand C., Penz M., Hofer H., Wrba F., Penner E., Schuppan D., Ferenci P. Cytokine 31:142-148(2005) · Mapped (18) |
| Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. Osterreicher C.H., Datz C., Stickel F., Hellerbrand C., Penz M., Hofer H., Wrba F., Penner E., Schuppan D., Ferenci P. J. Hepatol. 42:914-919(2005) · Mapped (26) |
| Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Graepler F., Verbeek B., Graeter T., Smirnow I., Kong H.L., Schuppan D., Bauer M., Vonthein R., Gregor M., Lauer U.M. Hepatology 41:879-886(2005) · Mapped (1) |
| Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy. von Moers A., Zwirner A., Reinhold A., Bruckmann O., van Landeghem F., Stoltenburg-Didinger G., Schuppan D., Herbst H., Schuelke M. Acta Neuropathol. 109:285-293(2005) · Mapped (13) |
| Hepatocyte growth factor and c-Met expression in rat and human liver fibrosis. Cramer T., Schuppan D., Bauer M., Pfander D., Neuhaus P., Herbst H. Liver Int. 24:335-344(2004) · Mapped (28) |